The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

Image result for pnas

“The therapeutic potential of cannabidiol (CBD), the major nonpsychoactive component of cannabis, was explored in murine collagen-induced arthritis (CIA).

CBD was administered after onset of clinical symptoms, and in both models of arthritis the treatment effectively blocked progression of arthritis. CBD was equally effective when administered i.p. or orally.

Clinical improvement was associated with protection of the joints against severe damage.

Taken together, these data show that CBD, through its combined immunosuppressive and anti-inflammatory actions, has a potent anti-arthritic effect in CIA.”

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC16904/

“In the present study, we report that CBD has a beneficial therapeutic action on established CIA, and we explore its mode of action.”   http://www.pnas.org/content/97/17/9561.long

Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report

“Stiff-person syndrome (SPS) is an uncommon and disabling disorder… Cannabis derivatives [tetrahydrocannabinol (THC) and cannabidiol (CBD)] are available as an oromucosal spray (Sativex(®)… Our objective is to report a case of seronegative SPS successfully treated with THC-CBD oromucosal spray… THC-CBC can be an option for SPS patient. Our case report suggests that THC-CBD oromucosal spray is an alternative treatment for patients with refractory SPS…”

http://www.ncbi.nlm.nih.gov/pubmed/22726074